The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Type 2 |
Drug: Canagliflozin 100 mg Drug: Canagliflozin 300 mg Drug: Placebo Drug: Metformin Drug: Sulphonylruea |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy |
- To assess the effect of canagliflozin relative to placebo on hemoglobin A1c (HbA1c). [ Time Frame: After 26 weeks of treatment with study drug. ] [ Designated as safety issue: No ]
- To assess the effect of study drug on HbA1c [ Time Frame: After 52 weeks of treatment ] [ Designated as safety issue: No ]
- To assess the effect of study drug on fasting plasma glucose (FPG), fasting plasma lipids, and fasting measure of beta-cell function [ Time Frame: After 26 and 52 weeks of treatment ] [ Designated as safety issue: No ]
- To assess the effect of study drug on the proportion of patients achieving an HbA1c <7 and <6.5% [ Time Frame: After 26 and 52 weeks of treatment ] [ Designated as safety issue: No ]
- To assess the effect of study drug on systolic and diastolic blood pressure and body weight [ Time Frame: After 26 and 52 weeks of treatment ] [ Designated as safety issue: No ]
- To assess the effect of study drug on time to rescue therapy and proportion of patients receiving rescue therapy [ Time Frame: After 26 and 52 weeks of treatment ] [ Designated as safety issue: No ]
| Enrollment: | 469 |
| Study Start Date: | May 2010 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 001
Canagliflozin 100 mg 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
|
Drug: Canagliflozin 100 mg
100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Drug: Metformin
The patient's stable dose of background metformin therapy should be continued throughout the study.
Drug: Sulphonylruea
The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
|
|
Experimental: 002
Canagliflozin 300 mg 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
|
Drug: Canagliflozin 300 mg
300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Drug: Metformin
The patient's stable dose of background metformin therapy should be continued throughout the study.
Drug: Sulphonylruea
The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
|
|
Placebo Comparator: 003
Placebo 1 placebo capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
|
Drug: Placebo
1 placebo capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Drug: Metformin
The patient's stable dose of background metformin therapy should be continued throughout the study.
Drug: Sulphonylruea
The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
|
Detailed Description:
Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (study drug assigned by chance), double-blind (neither the patient or the study doctor will know the name of the assigned treatment), placebo-controlled, parallel-group, 3-arm (3 treatment groups) multicenter study to determine the efficacy, safety, and tolerability of canagliflozin (100 mg and 300 mg) compared to placebo (a capsule that looks like all the other treatments but has no real medicine) in patients with T2DM who are not achieving an adequate response from current antihyperglycemic therapy with metformin and sulphonylurea to control their diabetes. Approximately 450 patients with T2DM who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control will receive once daily treatment with canagliflozin (100 mg or 300 mg) or placebo capsules for 52 weeks (includes 26 weeks of double-blind treatment followed by a 26-week extension period). In addition, all patients will take protocol-specified stable doses of metformin and sulphonylurea for the duration of the study. Patients will participate in the study for approximately 59 to 72 weeks. During the study, if a patient's fasting blood sugar remains high despite treatment with study drug, the patient will receive treatment with insulin (rescue therapy) consistent with local prescribing information. During treatment, patients will be monitored for safety by review of adverse events, results from laboratory tests, 12-lead electrocardiograms (ECGs), vital signs measurements, body weight, physical examinations, and self-monitored blood glucose (SMGB) measurements. The primary outcome measure in the study is to assess the effect of canagliflozin relative to placebo on hemoglobin A1c (HbA1c) after 26 weeks of treatment. Study drug will be taken orally (by mouth) once daily before the first meal each day unless otherwise specified. All patients will take single-blind placebo capsules for 2 weeks before randomization. After randomization, patients will take double-blind canagliflozin (100 mg or 300 mg) or matching placebo for 52 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea
- Patients in the study must have a HbA1c between >=7 and <=10.5%
- Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)
Exclusion Criteria:
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Contacts and Locations
Show 76 Study Locations| Study Director: | Janssen Research & Development, LLC C. Clinical Trial | Janssen Research & Development, LLC |
More Information
No publications provided
| Responsible Party: | Janssen Research & Development, LLC |
| ClinicalTrials.gov Identifier: | NCT01106625 History of Changes |
| Other Study ID Numbers: | CR017005, 28431754DIA3002 |
| Study First Received: | April 1, 2010 |
| Last Updated: | January 15, 2013 |
| Health Authority: | United States: Food and Drug Administration Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines |
Keywords provided by Janssen Research & Development, LLC:
|
Canagliflozin Placebo Metformin |
Sulphonylurea Hemoglobin A1c Type 2 diabetes mellitus |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013